Search Results for "En Vivo EVP6124 Alzheimer"

19:31 EDT 22nd October 2016 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Monitoring the Progression of Alzheimer Disease With tau-PET

A novel use of tau-PET imaging may facilitate precise in vivo diagnostics in Alzheimer disease, potentially enabling the creation of a neuropathological staging system. Brain

Breas Medical introduces Vivo 50 and Vivo 60 Pearl version

The highly successful Vivo 50 and Vivo 60 homecare ventilators are now further enhanced with a dedicated mouthpiece ventilation mode and other improvements. A complete package, called the "Pearl" vers...

Alzheimer's Association accelerates research on potential sex differences in Alzheimer's

(Alzheimer's Association) The first-ever Alzheimer's Association Sex and Gender in Alzheimer's (SAGA) research grant awards will provide $2.2 million to nine projects to advance understanding of the d...

[Comment] Alzheimer's disease risk: amyloid versus neurodegeneration

The National Institute on Ageing–Alzheimer's Association's (NIA-AA) criteria for preclinical Alzheimer's disease1 proposed the use of brain amyloid β (Aβ) deposition and neurodegeneration as bioma...

Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology

Alzheimer's Association awards $4.3 million to accelerate the launch of new drug treatment

(Alzheimer's Association) The Alzheimer's Association announces a new $4.3 million research grant for a new phase of the Dominantly Inherited Alzheimer's Network Trials Unit known as DIAN-TU Next Gene...

Vivo Capital closes new early stage fund

Vivo Capital closed its new Vivo Panda fund with more than $100 million to invest primarily in early stage healthcare companies, including biotech, medtech and diagnostics. Vivo said the new fund will...

Vivo Capital raises $100M-plus for health care fund

Over $100 million has been secured for the Vivo Panda fund, a new fund by Vivo Capital dedicated to early-stage medtech, diag -More- 

Matching PubMed Articles

Quantitative MRI to understand Alzheimer's disease pathophysiology.

The role of white matter damage in the progression of Alzheimer's disease and the associated cognitive symptoms is becoming increasingly clearer. This is partly because of the advent of diffusion tens...

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer's disease spectrum.

To determine the in vivo cortical spreading pattern of tau and amyloid and to establish positron emission tomography (PET) image-based tau staging in Alzheimer's disease (AD) spectrum.

Kallikrein-8 inhibition attenuates Alzheimer's pathology in mice.

Memory loss and increased anxiety are clinical hallmarks of Alzheimer's disease (AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is known to be up-regulated ...

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.

We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer d...

Alzheimer's disease research in Ibero America.

Search Whole site using Google

Quick Search
Advertisement Advertisement